Anke Klippel

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index9.7kcitations102works1.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(26), PI3K/AKT/mTOR signaling in cancer(18), Estrogen and related hormone effects(16), Multiple Myeloma Research and Treatments(11), Protein Degradation and Inhibitors(11)

Publications101 total

Abstract P4-12-24: Preclinical characterization of LY4045004, a next-generation, mutant-selective PI3Kα inhibitor
Clinical Cancer Research·2025
Abstract 4375: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS
Cancer Research·2025· 2 cited
Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors
Cancer Research·2025
Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Data from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025Open Access
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Cancer Research·2024· 13 citedOpen Access
Abstract 3316: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
Cancer Research·2024· 7 cited
page 1 of 6Next →

Frequent Co-authors

Lewis T. Williams(11), Klaus Giese(8), Jörg Kaufmann(6), Regine Kahmann(5), W. Michael Kavanaugh(4), Ansgar Santel(4), Sibylle Dames(4), W. Arnold(4), L T Williams(4), J A Escobedo(4), Anita K. Gandhi(3), Jian Kang(3), Courtney G. Havens(3), Anjan Thakurta(3), Rajesh Chopra(3), Gerald Apell(3), Manuela Aleku(3), Nicholas R. Cozzarelli(3), Daniel Tondera(3), Rolf Schwarzer(3)